Shaanxi Meibang Pharmaceutical Group Co., Ltd. (SHA:605033)

SHA:605033 Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	54.33	48.66	36.86	57.56	145.09	125.74
Depreciation & Amortization	31.2	31.2	21.75	20.87	15.47	12.48
Other Amortization	1.7	1.7	0.6	0.35	0.35	0.07
Loss (Gain) From Sale of Assets	-0.19	-0.19	0.03	-	-	-
Asset Writedown & Restructuring Costs	1.86	1.86	-	0.04	0.12	0.02
Loss (Gain) From Sale of Investments	-7.19	-7.19	-8.23	-4.58	-4.04	-0.91
Provision & Write-off of Bad Debts	-0.73	-0.73	-5.24	-2.47	5.99	3.65
Other Operating Activities	-25.65	18.88	19.83	16.49	8.19	13.65
Change in Accounts Receivable	16.78	16.78	66.49	98.49	-57.22	-105.49
Change in Inventory	11.74	11.74	67.59	85.48	92.31	-293.91
Change in Accounts Payable	103.29	103.29	80.15	67.44	-71.9	135.81
Operating Cash Flow	190.5	229.36	280.4	334.79	126.41	-108.75
Operating Cash Flow Growth	-0.86%	-18.20%	-16.25%	164.84%	-	-

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-173.52	-184.63	-158.81	-203.69	-109.29	-106.53
Sale of Property, Plant & Equipment	1.36	1.35	0.01	-	0.03	-
Investment in Securities	-30	-37	-388	80	68	-148
Other Investing Activities	8.57	7.88	9.33	6.51	6.86	2.61
Investing Cash Flow	-193.6	-212.39	-537.47	-117.18	-34.4	-251.92

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Short-Term Debt Issued	-	-	-	-	40	204.04
Long-Term Debt Issued	-	78	73	2.07	-	-
Total Debt Issued	158	78	73	2.07	40	204.04
Short-Term Debt Repaid	-	-	-	-	-67.05	-177
Long-Term Debt Repaid	-	-0.49	-1	-1.07	-	-
Total Debt Repaid	-73	-0.49	-1	-1.07	-67.05	-177
Net Debt Issued (Repaid)	85	77.51	72	1	-27.05	27.04
Issuance of Common Stock	-	-	-	-	25.57	391.84
Repurchase of Common Stock	-	-	-	-25.91	-	-
Common Dividends Paid	-24.49	-24.09	-28.24	-29.82	-26.67	-3.29
Other Financing Activities	22.05	-24.1	-18.91	-3.68	69.99	-65
Financing Cash Flow	82.55	29.32	24.85	-58.42	41.84	350.59

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Foreign Exchange Rate Adjustments	-0	-0	-	-	-	0.06
Net Cash Flow	79.45	46.28	-232.22	159.2	133.85	-10.02

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	16.97	44.74	121.59	131.1	17.12	-215.28
Free Cash Flow Growth	-42.51%	-63.21%	-7.26%	665.68%	-	-
Free Cash Flow Margin	1.77%	4.91%	13.73%	18.75%	1.89%	-25.55%
Free Cash Flow Per Share	0.13	0.33	0.89	0.98	0.13	-1.95
Levered Free Cash Flow	-146.77	-3.17	180.84	132.4	-48.62	-303.49
Unlevered Free Cash Flow	-146.37	-2.92	180.85	132.64	-48	-301.43

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash Income Tax Paid	3.9	3.79	13.33	15.85	26.36	19.05
Change in Working Capital	135.15	135.15	214.79	246.54	-44.75	-263.45

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 26, 2026

Data Sources Report a data error